No need to login to view prices!
|Create new account|
Due to technical maintenance the BIOKÉ webshop is closed until November 15th, 2020. We apologize for any inconvenience caused.
Using xCELLigence Real-Time Cell Analysis (RTCA), Sanofi Pasteur scientists have developed an assay for accurate viral titer determination that is 5-times less labor intensive and 3.5-times cheaper than conventional methods.
Accurate determination of viral titers is critical to vaccine development. Historically, titers have been determined using endpoint assays which are labor-intensive, expensive, and time consuming. This is increasingly problematic in modern production facilities where bioprocess optimization is performed using high-throughput cell culture reactors that can produce batches of virus faster than they can be analyzed. Looking for a solution to this bottleneck, Sanofi scientist David Gaillac and his coworkers have just described a transformative new approach for viral titer determination using xCELLigence RTCA instruments. On the basis of their findings the authors reported having made a major change in their workflow, stating that “The RTCA assay presented here is now being used for titration of viruses to support our bioprocess studies.” To view their complete comparative analysis, which was just published in the Journal of Virological Methods.
Figure: Viral titer determination using xCELLigence RTCA. (A) Monitoring the viral cytopathic effect that known quantities of yellow fever dengue virus induces in Vero cells. Note that the rate and extent of cytopathic effect correlates with the amount of virus used for infection. (B) Production of a standard curve which can be used for determining the concentration of virus in samples with unknown titer. This curve is produced by plotting the CITmed, the time required for the Cell Index to decrease to its median value, as a function of the known virus titer.